Oncology Drugs

Approx. Rs 11,000 / VialGet Latest Price

Product Details:

Botulinum Toxin Type A (Nabota) is indicated for the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm, hemifacial spasm or VII^th nerve disorders in patients 12 years or older.
Botulinum Toxin Type A (Nabota) is indicated for the correction of strabismus in patients 12 years or older.
Botulinum Toxin Type A (Nabota) is indicated for the treatment of spasmodic torticollis (cervical dystonia) in adults.
Botulinum Toxin Type A (Nabota) is indicated for the treatment of dynamic equinus foot deformity due to spasticity in pediatric cerebral palsy patients, two years of age or older.
Botulinum Toxin Type A (Nabota) is indicated for the temporary treatment of glabellar lines associated with corrugator and/or procerus muscle activity in adult patients below 65 years of age.
Botulinum Toxin Type A (Nabota) is indicated in the management of focal spasticity, including the treatment of spasticity associated with stroke in adults.
Botulinum Toxin Type A (Nabota) is indicated for the treatment of focal hyperhidrosis of the axilla.
Botulinum Toxin Type A (Nabota) is indicated for the temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow's feet and forehead lines) in adults.
Botulinum Toxin Type A (Nabota) is indicated for the prophylaxis of headaches in adults with chronic migraine.
Botulinum Toxin Type A (Nabota) is indicated for the treatment of urinary incontinence due to neurogenic detrusor overactivity e.g., spinal cord injury (SCI) or multiple sclerosis (MI) in adults.Dosage / Direction for UseBlepharospasm: Reconstituted Clostridium Botulinum Toxin Type A (see Table 1) is injected using a sterile, 27-30 gauge needle with or without electromyographic guidance.
Initial Recommended Dose: 1.25-2.5 units in (0.05-0.1 mL volume at each site) injected into the medial and lateral orbicularis oculi of the upper lid and into the lateral orbicularis oculi of the lower lid.
Injection placement may vary based on the patient's presentation. Avoiding injection near the levator palpebrae superioris may reduce the complication of ptosis. Avoiding medial lower lid injections and thereby reducing diffusion into the inferior oblique, may reduce the complication of diplopia. Ecchymosis occurs easily in the soft eyelid tissues. This can be prevented by applying pressure at the injection site immediately after the injection. The hazard of ectropion may be reduced by avoiding injection into the lower lid area.
In general, the initial effect of the injections is seen within 3 days and reaches a peak at 1-2 weeks post-treatment. Each treatment lasts approximately 3 months, following which the procedure can be repeated indefinitely. At repeat-treatment sessions, the dose may be increased up to 2-fold if the response from the initial treatment is considered insufficient (usually defined as an effect that does not last longer than 2 months). However, there appears to be little benefit obtainable from injecting >5 units/site. The initial dose should not exceed 25 units/eye. Normally, no additional benefit is conferred by treating more frequently than every 3 months. It is rare for the effect to be permanent.
In the management of blepharospasm, total dosing should not exceed 100 units every 12 weeks.

Approx. Rs 1,192 / VialGet Latest Price

Product Details:

Tetracosactide Injection is supplied as an ampoule for injection i.v., i.m. or s.c. Tetracosactide Zinc Injection (Synacthen Depot) i.m. in which the hormone is adsorbed on to zinc phosphate from which it is slowly released. This is the form used in the long tetracosactide test.

Approx. Rs 2,400 / BottleGet Latest Price

Product Details:

Erlotinib is used to treat certain types of non-small cell lung cancer that has spread to nearby tissues or to other parts of the body in patients who have already been treated with at least one other chemotherapy medication and have not gotten better.

Approx. Rs 5,900 / VialGet Latest Price

Product Details:

Zoladex is used in men to treat symptoms of prostate cancer, and in women to treat breast cancer or endometriosis. Zoladex is also used in women to prepare the lining of the uterus for endometrial ablation (a surgery to correct abnormal uterine bleeding.

Each Prefilled Injection contains:

• Goserelin acetate equivalent to Goserelin Ph. eur. 10.8 mg Peptide base in a long acting sustained release depot